Table 1 Patient characteristics according to ILAR subtype
nAge/years, median (range)Male (%)DMARD any (%)MTX (%)Biologic* (%)Oral steroid (%)No DMARD†
Systemic onset810.52 (3.51–15.12)6 (75)7 (88)5 (63)3 (38)3 (38)1 (12.5)
Polyarticular RF+109.92 (4.11–17.85)3 (30)7 (70)6 (60)1 (10)3 (38)2 (20)
Polyarticular RF1212.59 (2.85–15.13)2 (16)7 (58)6 (50)2 (17)3 (38)5 (41)
Persistent oligoarticular279.16 (2.06–28.74)7 (27)2 (7)2 (7)0025 (93)
Extended oligoarticular710.3 (4.03–17.96)2 (28)4 (57)1 (14)3 (43)03 (43)
Psoriatic419.3 (14.36–30.78)3 (75)2 (50)1 (25)1 (25)1 (25)2 (50)
Enthesitis214.25 (12.8–15.69)1 (50)2 (100)2 (100)01 (50)0
  • *Includes antitumour necrosis factor α agents and interleukin 1 receptor antagonist (IL1ra).

  • †Includes those taking only non-steroidal anti-inflammatorry drugs (NSAIDs) or relying only on local joint injections for disease control.

  • RF, rheumatoid factor; DMARD, disease-modifying antirheumatic drug; ILAR, International League of Associations for Rheumatology; MTX, methotrexate.